US Capital Global Securities Launches $15 Million Equity Investment in Clinical Stage Pharmaceutical Company
San Francisco-based private financial group engaged by pharmaceutical company as lead placement agent for capital raise.
SAN FRANCISCO, MARCH 2019 – US Capital Global Securities, an affiliate of US Capital Global, is offering to accredited investors a $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”).
S1 has a pipeline of drugs targeted at sexual dysfunction. Its leading drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to begin phase 2b trials. In phase 2a trials, Lorexys had strong results relative to competing drugs; one of which was sold for over $1B. The company intends to use proceeds from the raise to fund phase 2b trials for Lorexys.
Headquartered in San Francisco, US Capital Global is a full-service private financial group with an established track record in investment banking and capital raise services. Its registered broker-dealer affiliate, US Capital Global Securities, LLC, is acting as the exclusive placement agent for the equity raise for S1 Biopharma.
“We are excited to have US Capital Global Securities’ experienced team assist us in raising this Series A round of funding, which will enable S1 to complete phase 2b trials” said Nick Sitchon, CEO at S1 Biopharma. “US Capital Global’s support and expertise will enable S1 to reach a critical milestone on the path to FDA approval.”
“It has been a pleasure serving S1 as its lead financial advisor,” said Charles Towle, CEO at US Capital Global Securities. “Our shared enthusiasm for Lorexys’ strong phase 2a data was a key determinant in accepting this engagement. With US Capital Global Securities’ financial advisory and capital raise services, S1 is in a good position to advance its clinical trials. The opportunity to participate in this $15 million preferred equity investment is now open to eligible investors.”
About S1 Biopharma
S1 Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of sexual dysfunction in both women and men. The company’s development programs include first-in-class non-hormonal therapies designed to treat diminished sexual desire by restoring the natural balance of key neurotransmitters in the brain. The company’s lead product candidate, Lorexys, is currently positioned to advance to a Phase 2b clinical trial for the treatment of hypoactive sexual desire disorder (HSDD) in women. For more information, visit www.s1biopharma.com or follow S1 Biopharma on Facebook or Twitter (@s1biopharma).
About US Capital Global
US Capital Global Securities, LLC is the FINRA-licensed broker dealer division of US Capital Global that acts as placement agent for growth-stage companies, projects, and investment funds. Since 1998, the US Capital Global team has been committed to providing small and lower middle market businesses and investors with sophisticated debt, equity, and investment opportunities usually available only to larger middle market companies and institutional investors. US Capital Global manages direct investment funds and provides wealth management and capital raise services.
To learn more about US Capital Global Securities or this investment opportunity, email Charles Towle, Managing Partner, at charles@uscgs.com or call (415) 889-1010.
